Settipane G A, Kalliel J N, Klein D E
N Engl Reg Allergy Proc. 1987 Mar-Apr;8(2):95-7. doi: 10.2500/108854187778994482.
Of 158 asthmatic patients who were placed on inhaled beclomethasone, 15 (9.5%) developed either hoarseness (8), oral thrush (6), or both (1). When their adverse reactions subsided, seven of these 15 patients were rechallenged with inhaled beclomethasone. These included five cases who developed hoarseness and three who developed Candidiasis. One patient had both. Oral thrush did not recur, but 60% (3/5) of patients with hoarseness had recurrence. We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop hoarseness should not be re-challenged. Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.
在158例使用吸入性倍氯米松的哮喘患者中,15例(9.5%)出现了声音嘶哑(8例)、口腔念珠菌病(6例)或两者皆有(1例)。当这些不良反应消退后,这15例患者中的7例再次接受吸入性倍氯米松治疗。其中包括5例出现声音嘶哑的患者和3例出现念珠菌病的患者。有1例患者两者皆有。口腔念珠菌病未复发,但声音嘶哑患者中有60%(3/5)复发。我们得出结论,临床上有指征时患者可重新开始使用吸入性倍氯米松;然而,由于复发率高,出现声音嘶哑的患者不应再次接受挑战。同时使用口服泼尼松和局部倍氯米松可能会增加出现声音嘶哑或念珠菌病的风险。